公开(公告)号：US11912705B2

公开(公告)日：2024-02-27

申请号：US17407438

申请日：2021-08-20

Applicant: The Corporation of Mercer University

Inventor： Clinton E. Canal ,  Nader Moniri ,  Yiming Chen

IPC: C07D471/08 ,  C07D211/32 ,  C07D491/18 ,  C07D471/04 ,  C07D223/04

CPC classification number: C07D471/08 ,  C07D211/32 ,  C07D223/04 ,  C07D471/04 ,  C07D491/18

Abstract: Compounds, such as cathinone derivatives, and pharmaceutical formulations that include the compounds. The compounds may have a first selectivity for a first receptor subtype that is at least 10 times greater than a second selectivity for a second receptor subtype from the same class of receptors. Methods of treating patients, which may include administering to a patient a pharmaceutical formulation that includes a compound, such as a cathinone derivative.

公开(公告)号：US20220056029A1

公开(公告)日：2022-02-24

申请号：US17407438

申请日：2021-08-20

Applicant: The Corporation of Mercer University

Inventor： Clinton E. Canal ,  Nader Moniri ,  Yiming Chen

IPC: C07D471/08 ,  C07D211/32 ,  C07D223/04 ,  C07D471/04 ,  C07D491/18

Abstract: Compounds, such as cathinone derivatives, and pharmaceutical formulations that include the compounds. The compounds may have a first selectivity for a first receptor subtype that is at least 10 times greater than a second selectivity for a second receptor subtype from the same class of receptors. Methods of treating patients, which may include administering to a patient a pharmaceutical formulation that includes a compound, such as a cathinone derivative.

公开(公告)号：US20240246973A1

公开(公告)日：2024-07-25

申请号：US18435838

申请日：2024-02-07

Applicant: The Corporation of Mercer University

Inventor： Clinton E. Canal ,  Nader Moniri ,  Yiming Chen

IPC: C07D471/08 ,  C07D211/32 ,  C07D223/04 ,  C07D471/04 ,  C07D491/18

CPC classification number: C07D471/08 ,  C07D211/32 ,  C07D223/04 ,  C07D471/04 ,  C07D491/18

Abstract: Compounds, such as cathinone derivatives, and pharmaceutical formulations that include the compounds. The compounds may have a first selectivity for a first receptor subtype that is at least 10 times greater than a second selectivity for a second receptor subtype from the same class of receptors. Methods of treating patients, which may include administering to a patient a pharmaceutical formulation that includes a compound, such as a cathinone derivative.